New cocktail of drugs takes on rare brain cancer
NCT ID NCT07350850
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of four drugs—pirtobrutinib, sintilimab, rituximab, and high-dose methotrexate—as a first treatment for adults with newly diagnosed primary central nervous system lymphoma (PCNSL). About 77 participants will choose either this experimental combo or standard therapy. The main goal is to see if the combo leads to more complete remissions. Researchers will also track side effects and survival for up to 2 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pirtobrutinib, Sintilimab, Rituximab, and Methotrexate
What this could lead to
If successful, this combination could offer a more effective first-line treatment for primary CNS lymphoma, potentially improving response rates and survival.
What could go wrong
This is a phase 2 trial with only 77 participants, so results are preliminary. The combination may cause more side effects or not outperform standard therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China-Japan Union Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130033, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanxi Provincial People's Hospital
NOT_YET_RECRUITINGTaiyuan, Shanxi, 030012, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Fujian Medical University
RECRUITINGXiamen, Fujian, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China